CG Oncology
CGON
CG Oncology (CGON) earnings history
Most recent quarter
- Fiscal period
- Q3 2025
- Period end
- Sep 30, 2025
- EPS actual
- −$0.57
- EPS estimate
- −$0.56
- EPS surprise
- −1.97%
- Revenue surprise
- +2706.41%
- Revenue
- $1.7M
- Revenue estimate
- $59,364.00
- Reported
- Nov 14, 2025
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q3 2025 | Nov 14, 2025 | −$0.56 | −$0.57 | −1.97% | $1.7M | SEC |
| Q2 2025 | Aug 8, 2025 | −$0.47 | −$0.54 | −15.98% | $0.00 | SEC |
| Q1 2025 | May 13, 2025 | −$0.40 | −$0.45 | −11.50% | $52,000.00 | SEC |
| Q4 2024 | Mar 28, 2025 | −$0.35 | −$0.46 | −33.22% | $459,000.00 | SEC |
| Q2 2024 | Aug 8, 2024 | −$0.36 | −$0.28 | +21.35% | $111,000.00 | SEC |
Quarterly revenue
Frequently asked questions
When did CG Oncology (CGON) last report earnings?
CG Oncology last reported on Nov 14, 2025, covering fiscal Q3 2025.
Did CGON beat earnings estimates?
No. CG Oncology reported EPS of −$0.57 for Q3 2025 against a −$0.56 estimate — a 1.97% miss.
How much revenue did CGON report last quarter?
CG Oncology reported $1.7M in revenue for Q3 2025, against a consensus estimate of $59,364.00.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.